In the study (158), a patient with progressive metastatic pancreatic cancer received a single dose of genetically engineered therapy with autologous T cells which carried two allogeneic human leukocyte antigen-C*08:02-restricted TCRs directed against KRAS G12D mutations; the infusion dose was 16.2 × 109 cells. The gene discussed is KRAS; the disease is pancreatic neoplasm.